{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:51:17Z","timestamp":1776383477950,"version":"3.51.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"independent research grant from Bayer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-42342-0","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:44:17Z","timestamp":1773024257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal imaging biomarkers associated with recurrence of diabetic macular edema during aflibercept treat-and-extend therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Kiyoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaehwan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Young","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"42342_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00417-006-0516-y","volume":"245","author":"A Reichenbach","year":"2007","unstructured":"Reichenbach, A. et al. M\u00fcller cells as players in retinal degeneration and edema. Graefes Arch. Clin. Exp. Ophthalmol. 245, 627\u2013636 (2007).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol"},{"key":"42342_CR2","doi-asserted-by":"crossref","unstructured":"Zhang, J. et al. Diabetic macular Edema: Current understanding, molecular mechanisms and therapeutic implications. Cells 11, (2022).","DOI":"10.3390\/cells11213362"},{"key":"42342_CR3","doi-asserted-by":"crossref","unstructured":"Takamura, Y., Yamada, Y. & Inatani, M. Role of microaneurysms in the pathogenesis and therapy of diabetic macular Edema: A descriptive review. Medicina (Kaunas) 59, (2023).","DOI":"10.3390\/medicina59030435"},{"key":"42342_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2008.10.001","volume":"54","author":"N Bhagat","year":"2009","unstructured":"Bhagat, N., Grigorian, R. A., Tutela, A. & Zarbin, M. A. Diabetic macular Edema: Pathogenesis and treatment. Surv. Ophthalmol. 54, 1\u201332 (2009).","journal-title":"Surv. Ophthalmol."},{"key":"42342_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","volume":"63","author":"A Daruich","year":"2018","unstructured":"Daruich, A. et al. Mechanisms of macular Edema: Beyond the surface. Prog Retin Eye Res. 63, 20\u201368 (2018).","journal-title":"Prog Retin Eye Res."},{"key":"42342_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells, J. A. et al. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular Edema: Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123, 1351\u20131359 (2016).","journal-title":"Ophthalmology"},{"key":"42342_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","volume":"136","author":"NM Bressler","year":"2018","unstructured":"Bressler, N. M. et al. Persistent macular thickening following intravitreous Aflibercept, Bevacizumab, or Ranibizumab for central-involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 136, 257\u2013269 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"42342_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00417-022-05770-y","volume":"261","author":"SY Lim","year":"2023","unstructured":"Lim, S. Y. et al. Treat and extend regimen for diabetic macular oedema-a systematic review and meta-analysis. Graefes Arch. Clin. Exp. Ophthalmol. 261, 303\u2013315 (2023).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"42342_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.survophthal.2024.06.006","volume":"69","author":"M Parravano","year":"2024","unstructured":"Parravano, M. et al. Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers. Surv. Ophthalmol. 69, 893\u2013904 (2024).","journal-title":"Surv. Ophthalmol."},{"key":"42342_CR10","doi-asserted-by":"crossref","unstructured":"Kwan, C. C. & Fawzi, A. A. Imaging and biomarkers in diabetic Macular Edema and diabetic retinopathy. Curr Diab Rep 19, (2019).","DOI":"10.1007\/s11892-019-1226-2"},{"key":"42342_CR11","doi-asserted-by":"crossref","unstructured":"Kim, K., Lee, J. & Yu, S. Y. The effects of anti-vascular endothelial growth factor loading injections on retinal microvasculature in diabetic macular Edema. Transl Vis. Sci. Technol 13, (2024).","DOI":"10.1167\/tvst.13.12.37"},{"key":"42342_CR12","doi-asserted-by":"crossref","unstructured":"Chen, R. et al. Fluorescein leakage and optical coherence tomography angiography features of microaneurysms in diabetic retinopathy. J Diabetes Res (2022).","DOI":"10.1155\/2022\/7723706"},{"key":"42342_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.oret.2024.11.015","volume":"9","author":"RA Goldberg","year":"2025","unstructured":"Goldberg, R. A. et al. Resolution of angiographic macular leakage with faricimab versus Aflibercept in patients with diabetic macular Edema in YOSEMITE\/RHINE. Ophthalmol. Retina. 9, 515\u2013526 (2025).","journal-title":"Ophthalmol. Retina"},{"key":"42342_CR14","doi-asserted-by":"crossref","unstructured":"Liu, D. et al. Erythropoietin maintains VE-cadherin expression and barrier function in experimental diabetic retinopathy via inhibiting VEGF\/VEGFR2\/Src signaling pathway. Life Sci. 259, (2020).","DOI":"10.1016\/j.lfs.2020.118273"},{"key":"42342_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/aos.13294","volume":"95","author":"S Vujosevic","year":"2017","unstructured":"Vujosevic, S. et al. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol. 95, 464\u2013471 (2017).","journal-title":"Acta Ophthalmol."},{"key":"42342_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000525412","volume":"66","author":"L Tang","year":"2023","unstructured":"Tang, L., Luo, D., Qiu, Q., Xu, G. T. & Zhang, J. Hyperreflective foci in diabetic macular edema with subretinal fluid: Association with visual outcomes after Anti-VEGF treatment. Ophthalmic Res. 66, 39\u201347 (2023).","journal-title":"Ophthalmic Res."},{"key":"42342_CR17","doi-asserted-by":"crossref","unstructured":"Qin, S. et al. Hyperreflective foci and subretinal fluid are potential imaging biomarkers to evaluate Anti-VEGF effect in diabetic macular edema. Front Physiol 12, (2021).","DOI":"10.3389\/fphys.2021.791442"},{"key":"42342_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","volume":"125","author":"D Zur","year":"2018","unstructured":"Zur, D. et al. OCT Biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology 125, 267\u2013275 (2018).","journal-title":"Ophthalmology"},{"key":"42342_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.preteyeres.2017.11.002","volume":"64","author":"JS Joyal","year":"2018","unstructured":"Joyal, J. S., Gantner, M. L. & Smith, L. E. H. Retinal energy demands control vascular supply of the retina in development and disease: The role of neuronal lipid and glucose metabolism. Prog Retin Eye Res. 64, 131\u2013156 (2018).","journal-title":"Prog Retin Eye Res."},{"key":"42342_CR20","doi-asserted-by":"crossref","unstructured":"Iovino, C. et al. Choroidal vascularity index: An in-depth analysis of this novel optical coherence tomography parameter. J Clin. Med 9, (2020).","DOI":"10.3390\/jcm9020595"},{"key":"42342_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5935\/0004-2749.20160047","volume":"79","author":"VF Kniggendorf","year":"2016","unstructured":"Kniggendorf, V. F. et al. Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT. Arq. Bras. Oftalmol. 79, 155\u2013158 (2016).","journal-title":"Arq. Bras. Oftalmol"},{"key":"42342_CR22","doi-asserted-by":"crossref","unstructured":"Kocami\u015f, \u00d6., Temel, E., \u00d6zcan, G., A\u015fikgarip, N. & \u00d6rnek, K. Choroidal vascularity index after a single dose of intravitreal dexamethasone implant in patients with refractory diabetic macular oedema. Photodiagnosis Photodyn Ther 39, (2022).","DOI":"10.1016\/j.pdpdt.2022.102996"},{"key":"42342_CR23","doi-asserted-by":"crossref","unstructured":"Dou, N. et al. Choroidal vascularity index as a biomarker for visual response to antivascular endothelial growth factor treatment in diabetic macular edema. J Diabetes Res (2021).","DOI":"10.1155\/2021\/3033219"},{"key":"42342_CR24","doi-asserted-by":"crossref","unstructured":"Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 98, 741\u2013756 (1991).","DOI":"10.1016\/S0161-6420(13)38009-9"},{"key":"42342_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ajo.2015.04.021","volume":"160","author":"A Ishibazawa","year":"2015","unstructured":"Ishibazawa, A. et al. Optical coherence tomography angiography in diabetic retinopathy: A prospective pilot study. Am. J. Ophthalmol. 160, 35\u201344 (2015).","journal-title":"Am. J. Ophthalmol."},{"key":"42342_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/IAE.0000000000001938","volume":"39","author":"KB Schaal","year":"2019","unstructured":"Schaal, K. B. et al. Vascular abnormalities in diabetic retinopathy assessed with swept-source optical coherence tomography angiography widefield imaging. Retina 39, 79\u201387 (2019).","journal-title":"Retina"},{"key":"42342_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(18)30128-1","volume":"7","author":"C Sabanayagam","year":"2019","unstructured":"Sabanayagam, C. et al. Incidence and progression of diabetic retinopathy: A systematic review. Lancet Diabetes Endocrinol. 7, 140\u2013149 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"42342_CR28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen, Q. D. et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119, 789\u2013801 (2012).","journal-title":"Ophthalmology"},{"key":"42342_CR29","doi-asserted-by":"crossref","unstructured":"Sorour, O. A. et al. Morphological changes in intraretinal microvascular abnormalities after anti-VEGF therapy visualized on optical coherence tomography angiography. Eye Vis. (Lond) 7, (2020).","DOI":"10.1186\/s40662-020-00195-2"},{"key":"42342_CR30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/archopht.119.6.861","volume":"119","author":"P Hofman","year":"2001","unstructured":"Hofman, P., van Blijswijk, B. C., Gaillard, P. J., Vrensen, G. F. & Schlingemann, R. O. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: New insights into the pathogenesis of capillary nonperfusion. Arch. Ophthalmol. 119, 861\u2013866 (2001).","journal-title":"Arch. Ophthalmol."},{"key":"42342_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0002-9440(10)64869-9","volume":"160","author":"AM Joussen","year":"2002","unstructured":"Joussen, A. M. et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am. J. Pathol. 160, 501\u2013509 (2002).","journal-title":"Am. J. Pathol."},{"key":"42342_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.oret.2019.09.010","volume":"4","author":"Y Kaizu","year":"2020","unstructured":"Kaizu, Y. et al. Microaneurysm imaging using multiple En Face OCT angiography image averaging: Morphology and visualization. Ophthalmol. Retina. 4, 175\u2013186 (2020).","journal-title":"Ophthalmol. Retina"},{"key":"42342_CR33","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00417-020-04608-9","volume":"258","author":"K Mori","year":"2020","unstructured":"Mori, K. et al. Decrease in the number of microaneurysms in diabetic macular edema after anti-vascular endothelial growth factor therapy: implications for indocyanine green angiography-guided detection of refractory microaneurysms. Graefes Arch. Clin. Exp. Ophthalmol. 258, 735\u2013741 (2020).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"42342_CR34","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/aos.14706","volume":"99","author":"Y Yamada","year":"2021","unstructured":"Yamada, Y. et al. Microaneurysm density in residual oedema after anti-vascular endothelial growth factor therapy for diabetic macular oedema. Acta Ophthalmol. 99, 876\u2013883 (2021).","journal-title":"Acta Ophthalmol."},{"key":"42342_CR35","doi-asserted-by":"crossref","unstructured":"Yamada, Y. et al. Regional Variety of reduction in retinal thickness of diabetic macular edema after Anti-VEGF treatment. Medicina (Kaunas) 58, (2022).","DOI":"10.3390\/medicina58070933"},{"key":"42342_CR36","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1136\/bjophthalmol-2020-316952","volume":"105","author":"A Babiuch","year":"2021","unstructured":"Babiuch, A. et al. Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study. Br. J. Ophthalmol. 105, 1111\u20131115 (2021).","journal-title":"Br. J. Ophthalmol."},{"key":"42342_CR37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.oret.2019.06.005","volume":"3","author":"M Sugimoto","year":"2019","unstructured":"Sugimoto, M. et al. Multiple effects of intravitreal aflibercept on microvascular regression in eyes with diabetic macular edema. Ophthalmol. Retina. 3, 1067\u20131075 (2019).","journal-title":"Ophthalmol. Retina"},{"key":"42342_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.oret.2023.01.018","volume":"7","author":"K Sarici","year":"2023","unstructured":"Sarici, K. et al. Longitudinal quantitative ultrawide-field fluorescein angiography dynamics in the RUBY diabetic macular edema study. Ophthalmol. Retina. 7, 543\u2013552 (2023).","journal-title":"Ophthalmol. Retina"},{"key":"42342_CR39","unstructured":"Wykoff, C. C. et al. Ocular and systemic risk factors for disease worsening among patients with NPDR: Post hoc analysis of the PANORAMA trial. Ophthalmol Retina 27, (2023)."},{"key":"42342_CR40","doi-asserted-by":"crossref","unstructured":"Wong, T. Y. et al. YOSEMITE and RHINE Investigators. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology 131, 708\u2013723 (2024).","DOI":"10.1016\/j.ophtha.2023.12.026"},{"key":"42342_CR41","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ajo.2015.03.005","volume":"159","author":"S Sonoda","year":"2015","unstructured":"Sonoda, S. et al. Luminal and stromal areas of choroid determined by binarization method of optical coherence tomographic images. Am. J. Ophthalmol. 159, 1123\u20131131 (2015).","journal-title":"Am. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42342-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42342-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42342-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:06:19Z","timestamp":1776380779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42342-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42342"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42342-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12639"}}